{"Clinical Trial ID": "NCT00054275", "Intervention": ["INTERVENTION 1:", "Docetaxel and OSI-774", "Docetaxel IV for 1 hour once a week for 3 weeks and oral erlotinib once a day"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "A stage IV or a recurrent adenocarcinoma confirmed histologically in the breast", "A Measurable Disease", "The recurrence of the disease must not be within one year of taking docetaxel adjuvant", "Authorized stable brain metastases", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age", "- 18 years and over", "Gender", "Men or women", "Status of menopause", "Unspecified", "State of play", "ECOG (Eastern Cooperative Oncology Group) 0-2 OR", "Karnofsky 60-100%", "Life expectancy", "More than 6 months", "Haematopoietic", "WBC(White Blood Count) at least 3000/mm^3", "Number of platelets of at least 100 000/mm^3", "Absolute number of neutrophils at least 1500/mm^3", "- Hemoglobin at least 8 g/dL", "Hepatic", "Normal Bilirubine", "AST(aspartate aminotransferase)/ALT(alanine aminotransferase) not exceeding 2.5 times the upper limit of normal", "Renal", "- Normal creatinine OR", "At least 60 mL/min creatinine clearance", "No clinically significant proteinuria", "No significant impairment of renal function", "Cardiovascular disorders", "No Class III or IV heart disease from the New York Heart Association", "No symptomatic congestive heart failure", "No unstable breast angina", "No cardiac arrhythmia", "No insufficiently controlled hypertension", "Other", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception against barriers.", "No previous severe hypersensitivity reactions to docetaxel or polysorbate 80", "No other malignancy in the last 10 years, except non-melanoma inactive skin cancer, in situ cervix carcinoma, in situ breast carcinoma or bilateral breast cancer", "No infection in progress or active", "No peripheral neuropathy greater than Class 1", "No other uncontrolled concomitant medical conditions that would prevent participation in the study", "No psychiatric illness or social situation that would prevent compliance with the study", "THERAPE PRIOR CONCURENT:", "Biological therapy", "Previous authorised trastuzumab (Herceptin)", "- Chemotherapy", "See Disease Characteristics", "No previous chemotherapy for recurrent or metastatic disease", "Previous authorised adjuvant chemotherapy", "Endocrinotherapy", "\u2022 Pre-authorised hormonal treatment", "Radiotherapy", "Unspecified", "Surgery", "Unspecified", "Other", "No other competing search agent"], "Results": ["Performance measures:", "* Disease response (Measurement of tumour) by criteria RECIST v. 2000", "The response and progression will be evaluated in this study using the criteria of the Solid Tumour Response Assessment Criteria Committee (RECIST). RECIST criteria use only changes in the largest diameter (one-dimensional measure) of tumour lesions. Partial response: At least 30% of the sum of the longest diameter (LD) of the target lesions. Progressive disease: At least 20% of the sum of the LD of the target lesions. Stable disease: neither shrinkage nor sufficient increase.", "Time limit: after 6 courses (6 months) of combination therapy", "Results 1:", "Title of the arm/group: Docetaxel and OSI-774", "Description of the arm/group: docetaxel IV for 1 hour once a week for 3 weeks and oral erlotinib once a day", "Total number of participants analysed: 28", "Type of measurement: Number", "Unit of measure: participants Partial reply: 11", "\u2022 Disease progression: 14", "Stable disease: 3"], "Adverse Events": ["Undesirable Events 1:", "Total: 28/39 (71.79 per cent)", "Anemia 1/39 (2.56%)", "Leucopenia 4/39 (10.26 per cent)", "Neutropenia 4/39 (10.26 per cent)", "Chest pain 1/39 (2.56%)", "P\u00e9ricarditis 1/39 (2.56%)", "Sinus Tach. 1/39 (2.56%)", "Sinus Tachycardia 1/39 (2.56%)", "1/39 (2.56%)", "Diarrhoea 7/39 (17.95 per cent)", "Mucositis 3/39 (7.69 per cent)", "Nausea 2/39 (5.13%)", "- Vomiting [1]1/39 (2.56%)", "Fatigue 6/39 (15.38 per cent)"]}